Staging and prognostic factors in small cell lung cancer: a consensus report

Stahel, Rolf A.; Ginsberg, Robert J.; Havemann, K.; Hirsch, Fred R.; Ihde, Daniel C.; Jassem, Jacek; Karrer, K; Maurer, L. Herbert; Østerlind, Kell; Houtte, Paul Van

doi:10.1016/0169-5002(89)90156-6

Cited by 222 publications

(103 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although SCLC is very responsive to platinum-based chemotherapy and radiation (30), resistance to therapy quickly develops. The overall prognosis of SCLC is dismal (31,32). People with advanced stage SCLC usually survive for less than 1 year.…”

Section: Discussionmentioning

confidence: 99%

Grape Seed Procyanidin Extract Mediates Antineoplastic Effects against Lung Cancer via Modulations of Prostacyclin and 15-HETE Eicosanoid Pathways

Mao

Smoake

Park

et al. 2016

Cancer Prevention Research

View full text Add to dashboard Cite

Grape seed procyanidin extract (GSE) has been reported to exert antineoplastic properties via the inhibition of cyclooxygenase-2 (COX-2)/prostaglandin E 2 (PGE 2 ) eicosanoid pathways. In addition, ample data link carcinogenesis to inflammatory events involving other major eicosanoid metabolic pathways, including prostacyclin (PGI 2 ) and 15-hydroxyeicosatetraenoic acid (15-HETE). We therefore evaluated the effects of GSE on prostacyclin synthase (PTGIS)/PGI 2 and 15-lipoxigenase-2 (15-LOX-2)/15-HETE productions by human lung premalignant and malignant cells and correlated the findings with antiproliferative or proapoptotic effects of GSE. The effects of GSE on PGI 2 and 15-HETE productions by human bronchoalveolar lavage (BAL) cells ex vivo were also determined. We further evaluated the bioactivity of oral administration of leucoselect phytosome (a standardized GSE) in the lungs of subjects participating in a lung cancer chemoprevention trial, by comparing the antiproliferative effects of coculturing matched pre-versus posttreatment BAL fluids with lung premalignant and malignant cells. GSE significantly increased PGI 2 (as measured by 6-keto PGF1a) and 15-HETE productions by these cells. Transfections of PTGIS or 15-LOX-2-specific siRNA partially abrogated the antiproliferative or proapoptotic effects of GSE in lung premalignant and malignant cells, respectively. GSE also increased PTGIS and inhibition of caspase-3, and transfection of 15-LOX-2 siRNA abrogated the GSEinduced apoptosis in A549 cells. In addition, culture supernatants from ex vivo GSE-treated baseline BAL cells, as well as BAL fluids from subjects treated with leucoselect phytosome, significantly decreased proliferations of lung premalignant and malignant cells. Our findings support the continued investigation of GSE as an anti-neoplastic and chemopreventive agent against lung cancer. Cancer Prev Res; 9(12); 925-32. Ó2016 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

Grape Seed Procyanidin Extract Mediates Antineoplastic Effects against Lung Cancer via Modulations of Prostacyclin and 15-HETE Eicosanoid Pathways

Mao

Smoake

Park

et al. 2016

Cancer Prevention Research

View full text Add to dashboard Cite

show abstract

“…Patients were staged using standard CT scanning as either limited, with disease confined to one hemithorax, or extensive with disease beyond one hemithorax. Staging was performed using the current BALG and COIN guidelines, last updated by an IASLC workshop in 1989 (Stahal et al, 1989). The only difference in our group was that we used contralateral supraclavicular fossa nodes to indicate extensive disease.…”

Section: Methodsmentioning

confidence: 99%

Serum p53 antibodies: predictors of survival in small-cell lung cancer?

et al. 2000

View full text Add to dashboard Cite

Serum p53 antibodies have been shown to be a poor prognostic marker in resected non-small-cell lung cancer (NSCLC), but studies in small-cell lung cancer (SCLC) have been contradictory. We have studied the incidence of p53 antibodies in a large SCLC cohort treated at one oncology centre and correlated the results with survival. 231 patients (63% male, median age 65), diagnosed and treated for SCLC between 1987 and 1994 at The Royal Marsden Hospital NHS Trust, had sera stored pretreatment. All samples were tested for p53 antibodies (p53-Ab) using a standardized ELISA technique with a selection of strongly ELISA positive, weakly ELISA positive and negative samples being confirmed with immunoprecipitation. 54 patients were positive for p53-Ab (23%). The presence of a high titre of p53-Ab (titre ratio >5) appears to be associated with a survival advantage with a relative risk of death of 1.71 (95% CI: 1.14–2.58) in those without the antibody (P = 0.02). This study, the largest homogenous group so far looking at p53-Ab in SCLC, suggests that p53 antibody detection may have a role in predicting outcome in this type of cancer. © 2000 Cancer Research Campaign http://www.bjcancer.com

show abstract

“…The presence of ipsilateral pleural effusion was classified as limited disease. All the other conditions were considered as extensive disease (Stahel et al, 1989 (Pike and Robinson, 1970 (Siegel, 1956). Analysis of diseasefree survival or overall survival was done using the Kaplan-Meier method (Kaplan and Meier, 1958).…”

Section: Methodsmentioning

confidence: 99%

Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor

Leyvraz

Ketterer²,

Perey³

et al. 1995

Br J Cancer

View full text Add to dashboard Cite

Summary Dose intensity may be an important deterrminant of the outcome in cancer chemotherapy. but is often limited by cumulative haematological toxicity. The availability of haematopoietic growth factors such as granulocyte colony-stimulating factor (G-CSF) and of peripheral blood progenitor cell (PBPC) transplantation has allowed the development of a new treatment strategy in which several courses of high-dose combination chemotherapy are administered for the treatment of solid tumours. PBPCs were mobilised before chemotherapy using 12 or 30 Ljg kg day' G-CSF (Filgrastim) for 10 days, and were collected by 2-5 leucaphereses. The yields of mononuclear cells, colony-forming units and CD34-positive cells were similar at the two dose levels of Filgrastim, and the numbers of PBPCs were sufficient for rescue following multiple cycles of chemotherapy. High-dose chemotherapy (cyclophosphamide 2.5 g m-2 for 2 days, etoposide 300 mg m-for 3 days and cisplatin 50 mg m2 for 3 days) was administered sequentially for a median of three cycles (range 1-4) to ten patients. Following the 30 evaluable cycles, the median duration of leucopenia S 0.5 x 1091-1 and < 1.0 x 10 I`l was 7 and 8 days respectively. The median time of thrombopenia S 20 x 109 1' was 6 days. There was no cumulative haematological toxicity. The duration of leucopenia, but not of thrombopenia, was inversely related to the number of reinfused CFU-GM (granulocyte-macrophage colony-forming units). In the majority of patients, neurotoxicity and ototoxicity became dose limiting after three cycles of therapy. However, the average dose intensity delivered was about three times higher than in a standard regimen. The complete response rate in patients with small-cell lung cancers was 66% (95% CI 30-92%) and the median progression-free survival and overall survival were 13 months and 17 months respectively. These results are encouraging and should be compared, in a randomised fashion, with standard dose chemotherapy.

show abstract

Staging and prognostic factors in small cell lung cancer: a consensus report

Cited by 222 publications

References 21 publications

Grape Seed Procyanidin Extract Mediates Antineoplastic Effects against Lung Cancer via Modulations of Prostacyclin and 15-HETE Eicosanoid Pathways

Grape Seed Procyanidin Extract Mediates Antineoplastic Effects against Lung Cancer via Modulations of Prostacyclin and 15-HETE Eicosanoid Pathways

Serum p53 antibodies: predictors of survival in small-cell lung cancer?

Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor

Contact Info

Product

Resources

About